Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4 View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-04-17

AUTHORS

Zaina T. Al-Salama, Emma D. Deeks

ABSTRACT

A fixed-dose combination tablet comprising the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) was recently approved for the treatment of chronic HCV genotype 1 and 4 infection in the EU and the USA. In phase III trials, 12 or 16 weeks of treatment with once-daily elbasvir/grazoprevir (fixed-dose tablet or as individual agents), taken with or without ribavirin, generally provided high rates of sustained virological response at 12 weeks (SVR12) in treatment-naive and -experienced adult patients with chronic HCV genotype 1a, 1b or 4 infection, including those with or without compensated cirrhosis, HIV co-infection, inherited blood disorders or chronic kidney disease or patients receiving opioid agonist therapy or of Japanese origin. Elbasvir/grazoprevir was generally well tolerated. Thus, elbasvir/grazoprevir, with or without ribavirin, represents an effective new option for the treatment of adults with chronic HCV genotype 1 and 4 infection, including a number of difficult-to-treat populations. More... »

PAGES

911-921

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40265-017-0739-8

DOI

http://dx.doi.org/10.1007/s40265-017-0739-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084862402

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28417245


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzofurans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Coinfection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Approval", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Europe", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatitis C, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinoxalines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Springer, Mairangi Bay, Private Bag 65901, 0754, Auckland, New Zealand", 
          "id": "http://www.grid.ac/institutes/grid.420067.7", 
          "name": [
            "Springer, Mairangi Bay, Private Bag 65901, 0754, Auckland, New Zealand"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Al-Salama", 
        "givenName": "Zaina T.", 
        "id": "sg:person.013545340451.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013545340451.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Springer, Mairangi Bay, Private Bag 65901, 0754, Auckland, New Zealand", 
          "id": "http://www.grid.ac/institutes/grid.420067.7", 
          "name": [
            "Springer, Mairangi Bay, Private Bag 65901, 0754, Auckland, New Zealand"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Deeks", 
        "givenName": "Emma D.", 
        "id": "sg:person.0744471115.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744471115.81"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00535-016-1285-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036780607", 
          "https://doi.org/10.1007/s00535-016-1285-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13027-016-0071-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021714117", 
          "https://doi.org/10.1186/s13027-016-0071-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-04-17", 
    "datePublishedReg": "2017-04-17", 
    "description": "A fixed-dose combination tablet comprising the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier\u2122) was recently approved for the treatment of chronic HCV genotype 1 and 4 infection in the EU and the USA. In phase III trials, 12 or 16\u00a0weeks of treatment with once-daily elbasvir/grazoprevir (fixed-dose tablet or as individual agents), taken with or without ribavirin, generally provided high rates of sustained virological response at 12\u00a0weeks (SVR12) in treatment-naive and -experienced adult patients with chronic HCV genotype 1a, 1b or 4 infection, including those with or without compensated cirrhosis, HIV co-infection, inherited blood disorders or chronic kidney disease or patients receiving opioid agonist therapy or of Japanese origin. Elbasvir/grazoprevir was generally well tolerated. Thus, elbasvir/grazoprevir, with or without ribavirin, represents an effective new option for the treatment of adults with chronic HCV genotype 1 and 4 infection, including a number of difficult-to-treat populations.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40265-017-0739-8", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1084788", 
        "issn": [
          "0012-6667", 
          "1179-1950"
        ], 
        "name": "Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "77"
      }
    ], 
    "keywords": [
      "chronic HCV genotype 1", 
      "elbasvir/grazoprevir", 
      "HCV genotype 1", 
      "genotype 1", 
      "sustained virological response", 
      "phase III trials", 
      "chronic kidney disease", 
      "opioid agonist therapy", 
      "weeks of treatment", 
      "treatment of adults", 
      "fixed-dose combination tablet", 
      "HCV genotype 1a", 
      "virological response", 
      "treat population", 
      "agonist therapy", 
      "III trials", 
      "adult patients", 
      "kidney disease", 
      "genotype 1a", 
      "grazoprevir", 
      "effective new option", 
      "combination tablet", 
      "blood disorders", 
      "infection", 
      "ribavirin", 
      "patients", 
      "high rate", 
      "treatment", 
      "weeks", 
      "new options", 
      "cirrhosis", 
      "HIV", 
      "therapy", 
      "elbasvir", 
      "disease", 
      "trials", 
      "Japanese origin", 
      "disorders", 
      "adults", 
      "review", 
      "options", 
      "population", 
      "response", 
      "tablets", 
      "rate", 
      "number", 
      "origin", 
      "USA", 
      "EU"
    ], 
    "name": "Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4", 
    "pagination": "911-921", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084862402"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40265-017-0739-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28417245"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40265-017-0739-8", 
      "https://app.dimensions.ai/details/publication/pub.1084862402"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:02", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_740.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40265-017-0739-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40265-017-0739-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40265-017-0739-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40265-017-0739-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40265-017-0739-8'


 

This table displays all metadata directly associated to this object as RDF triples.

205 TRIPLES      21 PREDICATES      96 URIs      86 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40265-017-0739-8 schema:about N0ad5fbfb84704e6682f4bb6e30e14553
2 N0cef7d6ef83d439891a7de001c745506
3 N0d48f44ac33a4d02a1bb4ff59e6b7ba9
4 N25df394f826546f5a4b9019fabc84bfb
5 N385e5b4fdfcd4a1f8387584be2816f66
6 N3d6ee7609ac249f69037b43f2dd13042
7 N56e50c213c2448d39c267ced95f64f1c
8 N5b6e29d8d2974a53abe34aad5b40b6fc
9 N6b3ad23afe0a4e118a6049d76de67073
10 N79e063510dfd452da420d0cbd0c72991
11 N8e04983dc94a46eda60ad410dee43446
12 N9069cd363d064f6a8a9b4dbed53e3d1c
13 N91929e5439274c3d8e90d8c2b4bfa6c6
14 N9e96b2493f51408eb42bfe990fda363e
15 Nb8cca805b47d41138a92d02530090434
16 Nc03c9e8aa54a4b3698f1aee3c9839e44
17 Nca3ef3fe9dc74feaa5fbd4909e56422f
18 Ncc69225cb25e46e2b7ca434bc12beeda
19 Nd1fad3cdeda0465594817c0fdfe928f8
20 Nddaf7fa82e0a42e2935fa72f6bf83e88
21 anzsrc-for:11
22 anzsrc-for:1103
23 schema:author N0b789c57adff4315822f1a19cb0ca3b2
24 schema:citation sg:pub.10.1007/s00535-016-1285-y
25 sg:pub.10.1186/s13027-016-0071-z
26 schema:datePublished 2017-04-17
27 schema:datePublishedReg 2017-04-17
28 schema:description A fixed-dose combination tablet comprising the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) was recently approved for the treatment of chronic HCV genotype 1 and 4 infection in the EU and the USA. In phase III trials, 12 or 16 weeks of treatment with once-daily elbasvir/grazoprevir (fixed-dose tablet or as individual agents), taken with or without ribavirin, generally provided high rates of sustained virological response at 12 weeks (SVR12) in treatment-naive and -experienced adult patients with chronic HCV genotype 1a, 1b or 4 infection, including those with or without compensated cirrhosis, HIV co-infection, inherited blood disorders or chronic kidney disease or patients receiving opioid agonist therapy or of Japanese origin. Elbasvir/grazoprevir was generally well tolerated. Thus, elbasvir/grazoprevir, with or without ribavirin, represents an effective new option for the treatment of adults with chronic HCV genotype 1 and 4 infection, including a number of difficult-to-treat populations.
29 schema:genre article
30 schema:isAccessibleForFree false
31 schema:isPartOf Nb530f13714ba4d0089e46c22ff392b9a
32 Nc4be0a3ebd624bff95d0087e3b394f2c
33 sg:journal.1084788
34 schema:keywords EU
35 HCV genotype 1
36 HCV genotype 1a
37 HIV
38 III trials
39 Japanese origin
40 USA
41 adult patients
42 adults
43 agonist therapy
44 blood disorders
45 chronic HCV genotype 1
46 chronic kidney disease
47 cirrhosis
48 combination tablet
49 disease
50 disorders
51 effective new option
52 elbasvir
53 elbasvir/grazoprevir
54 fixed-dose combination tablet
55 genotype 1
56 genotype 1a
57 grazoprevir
58 high rate
59 infection
60 kidney disease
61 new options
62 number
63 opioid agonist therapy
64 options
65 origin
66 patients
67 phase III trials
68 population
69 rate
70 response
71 review
72 ribavirin
73 sustained virological response
74 tablets
75 therapy
76 treat population
77 treatment
78 treatment of adults
79 trials
80 virological response
81 weeks
82 weeks of treatment
83 schema:name Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4
84 schema:pagination 911-921
85 schema:productId N1af17afe19b54819bde0566ab793f433
86 N41470028c03a4dc399361a10d64c4db4
87 Nd2a3d88ac00f474384a817125f7411ac
88 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084862402
89 https://doi.org/10.1007/s40265-017-0739-8
90 schema:sdDatePublished 2022-11-24T21:02
91 schema:sdLicense https://scigraph.springernature.com/explorer/license/
92 schema:sdPublisher Ne4a664c684e44bfaa5f2afdfed15875f
93 schema:url https://doi.org/10.1007/s40265-017-0739-8
94 sgo:license sg:explorer/license/
95 sgo:sdDataset articles
96 rdf:type schema:ScholarlyArticle
97 N0ad5fbfb84704e6682f4bb6e30e14553 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name United States
99 rdf:type schema:DefinedTerm
100 N0b789c57adff4315822f1a19cb0ca3b2 rdf:first sg:person.013545340451.66
101 rdf:rest N56d96fab0b29433696c0d5ca8867516f
102 N0cef7d6ef83d439891a7de001c745506 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Quinoxalines
104 rdf:type schema:DefinedTerm
105 N0d48f44ac33a4d02a1bb4ff59e6b7ba9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Young Adult
107 rdf:type schema:DefinedTerm
108 N1af17afe19b54819bde0566ab793f433 schema:name dimensions_id
109 schema:value pub.1084862402
110 rdf:type schema:PropertyValue
111 N25df394f826546f5a4b9019fabc84bfb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Europe
113 rdf:type schema:DefinedTerm
114 N385e5b4fdfcd4a1f8387584be2816f66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Middle Aged
116 rdf:type schema:DefinedTerm
117 N3d6ee7609ac249f69037b43f2dd13042 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Hepatitis C, Chronic
119 rdf:type schema:DefinedTerm
120 N41470028c03a4dc399361a10d64c4db4 schema:name pubmed_id
121 schema:value 28417245
122 rdf:type schema:PropertyValue
123 N56d96fab0b29433696c0d5ca8867516f rdf:first sg:person.0744471115.81
124 rdf:rest rdf:nil
125 N56e50c213c2448d39c267ced95f64f1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Adult
127 rdf:type schema:DefinedTerm
128 N5b6e29d8d2974a53abe34aad5b40b6fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Benzofurans
130 rdf:type schema:DefinedTerm
131 N6b3ad23afe0a4e118a6049d76de67073 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Drug Approval
133 rdf:type schema:DefinedTerm
134 N79e063510dfd452da420d0cbd0c72991 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Coinfection
136 rdf:type schema:DefinedTerm
137 N8e04983dc94a46eda60ad410dee43446 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name HIV Infections
139 rdf:type schema:DefinedTerm
140 N9069cd363d064f6a8a9b4dbed53e3d1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Aged, 80 and over
142 rdf:type schema:DefinedTerm
143 N91929e5439274c3d8e90d8c2b4bfa6c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 N9e96b2493f51408eb42bfe990fda363e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Adolescent
148 rdf:type schema:DefinedTerm
149 Nb530f13714ba4d0089e46c22ff392b9a schema:issueNumber 8
150 rdf:type schema:PublicationIssue
151 Nb8cca805b47d41138a92d02530090434 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Randomized Controlled Trials as Topic
153 rdf:type schema:DefinedTerm
154 Nc03c9e8aa54a4b3698f1aee3c9839e44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Aged
156 rdf:type schema:DefinedTerm
157 Nc4be0a3ebd624bff95d0087e3b394f2c schema:volumeNumber 77
158 rdf:type schema:PublicationVolume
159 Nca3ef3fe9dc74feaa5fbd4909e56422f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Antiviral Agents
161 rdf:type schema:DefinedTerm
162 Ncc69225cb25e46e2b7ca434bc12beeda schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Drug Combinations
164 rdf:type schema:DefinedTerm
165 Nd1fad3cdeda0465594817c0fdfe928f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Imidazoles
167 rdf:type schema:DefinedTerm
168 Nd2a3d88ac00f474384a817125f7411ac schema:name doi
169 schema:value 10.1007/s40265-017-0739-8
170 rdf:type schema:PropertyValue
171 Nddaf7fa82e0a42e2935fa72f6bf83e88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Quality of Life
173 rdf:type schema:DefinedTerm
174 Ne4a664c684e44bfaa5f2afdfed15875f schema:name Springer Nature - SN SciGraph project
175 rdf:type schema:Organization
176 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
177 schema:name Medical and Health Sciences
178 rdf:type schema:DefinedTerm
179 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
180 schema:name Clinical Sciences
181 rdf:type schema:DefinedTerm
182 sg:journal.1084788 schema:issn 0012-6667
183 1179-1950
184 schema:name Drugs
185 schema:publisher Springer Nature
186 rdf:type schema:Periodical
187 sg:person.013545340451.66 schema:affiliation grid-institutes:grid.420067.7
188 schema:familyName Al-Salama
189 schema:givenName Zaina T.
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013545340451.66
191 rdf:type schema:Person
192 sg:person.0744471115.81 schema:affiliation grid-institutes:grid.420067.7
193 schema:familyName Deeks
194 schema:givenName Emma D.
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744471115.81
196 rdf:type schema:Person
197 sg:pub.10.1007/s00535-016-1285-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1036780607
198 https://doi.org/10.1007/s00535-016-1285-y
199 rdf:type schema:CreativeWork
200 sg:pub.10.1186/s13027-016-0071-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1021714117
201 https://doi.org/10.1186/s13027-016-0071-z
202 rdf:type schema:CreativeWork
203 grid-institutes:grid.420067.7 schema:alternateName Springer, Mairangi Bay, Private Bag 65901, 0754, Auckland, New Zealand
204 schema:name Springer, Mairangi Bay, Private Bag 65901, 0754, Auckland, New Zealand
205 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...